Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Minerva Neurosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
NERV
Nasdaq
2834
https://www.minervaneurosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Minerva Neurosciences Inc
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
- Feb 27th, 2024 1:00 pm
Minerva schizophrenia drug rejected by FDA
- Feb 27th, 2024 11:31 am
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
- Feb 22nd, 2024 12:00 pm
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
- Nov 7th, 2023 12:30 pm
12 Best Performing Biotech Stocks in 2023
- Oct 20th, 2023 5:22 pm
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
- Aug 1st, 2023 11:30 am
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
- Jun 28th, 2023 12:30 pm
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
- Jun 9th, 2023 1:55 pm
What Makes Minerva Neurosciences (NERV) a New Buy Stock
- May 18th, 2023 4:00 pm
Q1 2023 Minerva Neurosciences Inc Earnings Call
- May 16th, 2023 1:57 am
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
- May 15th, 2023 11:30 am
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
- May 10th, 2023 12:00 pm
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
- May 8th, 2023 12:30 pm
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
- May 1st, 2023 11:00 am
Scroll